UNITY Biotechnology to Highlight Foselutoclax (UBX1325) Data at Ophthalmology Day
Key Insights
UNITY Biotechnology will host an Ophthalmology Day on October 15, 2024, focusing on its ASPIRE study.
The ASPIRE study evaluates foselutoclax (UBX1325) against aflibercept for diabetic macular edema (search) (DME).
Twenty-four-week safety and efficacy data from the ASPIRE study are expected in Q1 2025.
UNITY Biotechnology, Inc. (NASDAQ: UBX) is set to host an in-person and virtual Ophthalmology Day on Tuesday, October 15, 2024, in New York, NY, to update investors and analysts on its ongoing clinical programs. A key focus of the event will be the Phase 2b ASPIRE study, which is evaluating foselutoclax (UBX1325) in a head-to-head comparison with aflibercept for the treatment of diabetic macular edema (search) (DME). The company anticipates releasing 24-week safety and efficacy data in the first quarter of 2025, followed by 36-week data in the second quarter of 2025.
The Ophthalmology Day event will feature presentations from prominent ophthalmology key opinion leaders (KOLs) and UNITY Biotechnology management. Discussions will include the senolytic therapeutic hypothesis, the UBX1325 clinical development plan, and a retina expert roundtable. The KOLs include Robert Bhisitkul, M.D., Ph.D., Arshad Khanani, M.D., MA, FASRS, and Dante Pieramici, M.D.
Foselutoclax (UBX1325) Clinical Development
UBX1325, an investigational compound, is a potent small molecule inhibitor of BCL-xL (search), a member of the BCL-2 family of apoptosis-regulating proteins. It is designed to inhibit the function of proteins that senescent cells rely on for survival. The Phase 2 BEHOLD study in patients with DME previously demonstrated that a single injection of UBX1325 resulted in a statistically significant and clinically meaningful improvement in mean best-corrected visual acuity (BCVA) through 48 weeks compared to sham treatment.
Addressing Unmet Needs in DME
Diabetic macular edema (search) (DME) is a common complication of diabetic retinopathy (search) and a leading cause of vision loss in adults. Current treatments, such as anti-VEGF injections, require frequent administration and may not be effective for all patients. Retina experts at the event will address the evolving therapeutic landscape and the potential of UBX1325 to address unmet needs in DME.
Event Details and Access
The event will take place at the Park Terrace Hotel in New York, NY, from 8:00 a.m. to 9:30 a.m. ET. A live webcast will be available for virtual attendees through the "Investors & Media" section of the company’s website. Archived replays will be accessible for 90 days following the event.